Inkampani Array BioPharma Inc, ibinimetinib, UBraftovi, encorafenib, UMektovi, Pfizer
I-Encorafenib ene-binimetinib igunyazwe yi-FDA yokwelashwa komdlavuza wamaphaphu we-metastatic ongewona omncane ngokuguqulwa kwe-BRAF V600E
I-Food and Drug Administration (i-FDA) igunyaze i-Encorafenib (i-Braftovi, i-Array BioPharma Inc., inkampani ephethwe ngokugcwele ye-Pfizer) kanye ne-binimetinib (Mektovi, Array BioPharma Inc.) ngoNovemba 2023 njengemithi engasetshenziswa ukulungisa inkinga.
UBosulif, IBosutinib, isifo esingelapheki somdlavuza wegazi, I-CML, Pfizer
I-Bosutinib igunyazwe yi-FDA yeziguli zezingane ezine-myelogenous leukemia engapheli
Nov 2023: Ezigulini zezingane ezinonyaka owodwa nangaphezulu ezinesigaba esingapheli (CP) Ph+ chronic myelogenous leukemia (CML), esanda kutholakala (ND) noma engazweli noma engabekezeleli (R/I) ekwelashweni kwangaphambilini, iFood and Drug Admini. .
Pfizer, I-TALAPRO-2, I-Talazoparib
I-Talazoparib ene- enzalutamide igunyazwe yi-FDA yomdlavuza wendlala yesinye we-HRR oguquliwe we-metastatic castration-resistant prostate
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
I-ADVL0912, i-anaplastic lymphoma kinase, i-lymphoma, I-NCT00939770, Pfizer, I-Xalkori
I-Crizotinib ivunyelwe yi-FDA ye-ALK-positive inflammatory myofibroblastic tumor
Julayi 2022: I-Crizotinib (Xalkori, Pfizer Inc.) yanikezwa imvume yi-Food and Drug Administration (FDA) yokwelapha abantu abadala kanye neziguli zezingane ezinonyaka ongu-1 ubudala nangaphezulu ezitholwe zinezinkinga ezingalawuleki, eziphindelelayo.
ALK, B7461006, i-crizotinib, I-Lorbrena, iloratinib, I-NCT03052608, Pfizer, IVentana ALK, Izinhlelo zeVentana Medical
ILorlatinib ivunyelwe yi-FDA ekwelashweni kwe-NSCLC ye-ALK-positive metastatic.
Agasti 2021: I-Lorlatinib (i-Lorbrena, i-Pfizer Inc.) ithole ukuvunyelwa okujwayelekile kwe-FDA kweziguli ezinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) ezinamathumba azo yi-anaplastic lymphoma kinase (ALK) -positive, njengoba kunqunywe uhlelo lokusebenza lwe-FDA ..
i-anaplastic lymphoma kinase, B7461006, I-CDx Assay, Ukuphathwa Kwezokudla Nezidakamizwa, I-Lorbrena, iloratinib, I-NCT03052608, I-NSCLC, Pfizer, IVentana ALK, Izinhlelo zeVentana Medical
ILorlatinib ivunyelwe yi-FDA ekwelashweni kwe-NSCLC ye-ALAS-positive metastatic
Agasti 2021: I-Lorlatinib (i-Lorbrena, i-Pfizer Inc.) ithole ukuvunyelwa okujwayelekile kwe-FDA kweziguli ezinomdlavuza we-metastatic non-small cell lung cancer (NSCLC) ezinamathumba azo yi-anaplastic lymphoma kinase (ALK) -positive, njengoba kunqunywe uhlelo lokusebenza lwe-FDA ..
Bharat Biotech, ICoronavirus, I-Covaxin, Covid, Umgomo we-covid, I-Covishield, Pfizer
Umuthi wokugoma we-COVID-19 - Konke obufuna ukukwazi
UDkt. Julie Gralow uphendula imibuzo ngomgomo we-COVID-19. Singaqiniseka kanjani ukuthi imithi yokugoma iphephile uma yenziwa futhi yagunyazwa esikhathini esifushane kangaka? Umphakathi wezokwelapha ubusebenzela ukwenza imigomo ye-COVID-19 itholakale.